Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy

Rohracher, Alexandra
Höfler, Julia
Kalss, Gudrun
Neuray, Caroline
Dobesberger, Judith
Kuchukhidze, Giorgi
Leitinger, Markus
Trinka, Eugen
BRIGO, Francesco

Open link

Publication date

January 2016

DOI

10.1080/14656566.2016.1195810

Publisher

Informa UK Limited

Abstract

The non-competitive α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) - receptor antagonist perampanel (PER) was approved in 2015 for treatment of primary generalized tonic-clonic seizures (pGTCS). The aim of this narrative review is to summarize available data on pharmacological properties, efficacy and tolerability of PER in pGTCs

Extracted data

We use cookies to provide a better user experience.

Data Protection

Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy

Abstract

Extracted data

Perampanel for the treatment of primary generalized tonic-clonic seizures in idiopathic generalized epilepsy

Abstract

Extracted data

Related items

Related items